-
Mashup Score: 22022 Credit Card Debt Statistics | LendingTree - 1 year(s) ago
Americans’ total credit card balance is $925 billion in the third quarter of 2022, according to the latest data from the Federal Reserve Bank of New York.
Source: LendingTreeCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 1
Real-World Evidence of Patients with mCRPC Treated with Cabazitaxel, CARD study, efficacy and safety of cabazitaxel as compared with an androgen-receptor-signaling inhibitor.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Real-world evidence of pts with metastatic castration-resistant #ProstateCancer treated with cabazitaxel: comparison with the randomized clinical study #CARD. #BeyondTheAbstract on UroToday > https://t.co/OcoXx9UjWI @SFreedlandMD @CaPsurvivorship @pcan_journal @OudardStephane https://t.co/Q7obsvzBW6
-
-
Mashup Score: 0
Real-World Evidence of Patients with mCRPC Treated with Cabazitaxel, CARD study, efficacy and safety of cabazitaxel as compared with an androgen-receptor-signaling inhibitor.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Real-world evidence of pts with metastatic castration-resistant #ProstateCancer treated with cabazitaxel: comparison with the randomized clinical study #CARD. #BeyondTheAbstract on UroToday > https://t.co/OcoXxabUOg @SFreedlandMD @CaPsurvivorship @pcan_journal @OudardStephane https://t.co/Qwcqrl9K6k
-
-
Mashup Score: 0Therapy Resistance Identified in Circulating Tumor Cell Morphologic Sub-Types Present Prior to Treatment in the CARD Trial - Cora Sternberg - 2 year(s) ago
Alicia Morgans and Cora Sternberg discuss the ESMO 2021 presentation on the impact of circulating tumor cell (CTC) morphologic sub-types in blood samples prior to treatment in the CARD trial. The objective of this pre-planned CARD Trial, EPIC biomarker study was to analyze the morphology of CTC subtypes in a liquid biopsy looking at chromosomal instability. Dr. Sternberg highlights the findings…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Therapy resistance identified in circulating tumor cell morphologic sub-types present prior to treatment in the #CARD trial. @cnsternberg @WCMEnglanderIPM joins @CaPsurvivorship @DanaFarber in this discussion on UroToday > https://t.co/KeDM8ZwO91 @nyphospital @NEJM @sanofi https://t.co/Jfuv4NGsRc
-
-
Mashup Score: 1
Real-World Evidence of Patients with mCRPC Treated with Cabazitaxel, CARD study, efficacy and safety of cabazitaxel as compared with an androgen-receptor-signaling inhibitor.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Real-world evidence of pts with metastatic castration-resistant #ProstateCancer treated with cabazitaxel: comparison with the randomized clinical study #CARD. #BeyondTheAbstract on UroToday > https://t.co/OcoXx9UjWI @SFreedlandMD @CaPsurvivorship @pcan_journal @OudardStephane https://t.co/Rkmzblm9yz
-
-
Mashup Score: 2Therapy Resistance Identified in Circulating Tumor Cell Morphologic Sub-Types Present Prior to Treatment in the CARD Trial - Cora Sternberg - 2 year(s) ago
Alicia Morgans and Cora Sternberg discuss the ESMO 2021 presentation on the impact of circulating tumor cell (CTC) morphologic sub-types in blood samples prior to treatment in the CARD trial. The objective of this pre-planned CARD Trial, EPIC biomarker study was to analyze the morphology of CTC subtypes in a liquid biopsy looking at chromosomal instability. Dr. Sternberg highlights the findings…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
Therapy resistance identified in circulating tumor cell morphologic sub-types present prior to treatment in the #CARD trial. @cnsternberg @WCMEnglanderIPM joins @CaPsurvivorship @DanaFarber in this discussion on UroToday > https://t.co/KeDM8ZwO91 @nyphospital @NEJM @sanofi https://t.co/Kw6XNl330B
-
-
Mashup Score: 0
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide, results of the CARD study, older patients with mCRPC, Febrile neutropenia (FN), Older patients with prostate cancer, efficacy and safety of cabazitaxel.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Efficacy and safety of cabazitaxel vs abiraterone or enzalutamide in older patients with #mCRPC in the #CARD study. #BeyondTheAbstract with @cnsternberg @WCMEnglanderIPM. #ReadNow on UroToday > https://t.co/jJngwCy0jp @sanofi @EUplatinum https://t.co/k3L8qiL7VH
-
-
Mashup Score: 0Therapy Resistance Identified in Circulating Tumor Cell Morphologic Sub-Types Present Prior to Treatment in the CARD Trial - Cora Sternberg - 2 year(s) ago
Alicia Morgans and Cora Sternberg discuss the ESMO 2021 presentation on the impact of circulating tumor cell (CTC) morphologic sub-types in blood samples prior to treatment in the CARD trial. The objective of this pre-planned CARD Trial, EPIC biomarker study was to analyze the morphology of CTC subtypes in a liquid biopsy looking at chromosomal instability. Dr. Sternberg highlights the findings…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Therapy resistance identified in circulating tumor cell morphologic sub-types present prior to treatment in the #CARD trial. @cnsternberg @WCMEnglanderIPM joins @CaPsurvivorship @DanaFarber in this discussion on UroToday > https://t.co/KeDM8ZwO91 @nyphospital @NEJM @sanofi https://t.co/391TTIuCye
-
-
Mashup Score: 0Real-World Evidence For Patients with mCRPC Treated with Cabazitaxel - Ronald de Wit - 2 year(s) ago
The CARD study was a head-to-head comparison of cabazitaxel chemotherapy versus either abiraterone or enzalutamide in mCRPC patients who had been exposed to one series of the docetaxel chemotherapy cycle and the alternative AR-targeted agents. There was a 30% reduction in the risk of death by cabazitaxel chemotherapy. This data was presented at the 2019 ESMO meeting by Ronald de Wit, MD, Ph.D….
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
Real-world evidence for patients with #mCRPC treated with #cabazitaxel. Ronald de Wit, MD, PhD @ErasmusMC joins @CaPsurvivorship @DanaFarber highlighting the posthoc analysis completed in a large real-world dataset within the #CARD-eligible population > https://t.co/aJ7zP7sEOm https://t.co/s7HbL6ricU
-
-
Mashup Score: 0
In the PHASE 4 CARD trial, cabazitaxel significantly improved radiographic progression-free survival (rPFS) and overall survival versus abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer who had received docetaxel and progressed within 12 months with the alternative androgen-signaling-targeted inhibitor. In this conversation, Alicia Morgans, MD, MPH,…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Evaluating circulating tumor cells in patients on the #CARD trial. @EfstathiouEleni @MDAndersonNews joins @CaPsurvivorship @DanaFarber to highlight a preplanned biomarker analysis of patients on the CARD trial. #WatchNow on UroToday > https://t.co/q4GZmHzvcC @NEJM @sanofi https://t.co/2hqktjEE5X
-
RT @efipm: 📌 2022 #Credit #Card Debt Statistics @LendingTree https://t.co/mfSBG0u192 ✍️ Scary US stats! @linasbeliunas @dionlisle @psb_d…